GlobalData on MSN2mon
ITM’s radiotherapeutic beats out standard-of-care in Phase III trialPatients were randomised to receive ITM-11 with a nephroprotective amino acid solution every three months, or Afinitor 10 mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback